Clinical Consequences and Functional Impact of the Rare S737F CFTR Variant and Its Responsiveness to CFTR Modulators
Authors:
- Vito TerlizziVito Terlizzi
- Emanuela PesceEPEmanuela Pesce
- Valeria CapurroVCValeria Capurro
- Valeria TomatiVTValeria Tomati
- Mariateresa LenaMLMariateresa Lena
- Cristina PastorinoCPCristina Pastorino
- Renata BocciardiRBRenata Bocciardi
- Federico ZaraFZFederico Zara
- Claudia CentroneCCClaudia Centrone
- Giovanni TaccettiGTGiovanni Taccetti
- Carlo CastellaniCCCarlo Castellani
- Nicoletta PedemonteNPNicoletta Pedemonte
Open Access
- 31 March 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (7) , 6576
Abstract
S737F is a Cystic Fibrosis (CF) transmembrane conductance regulator (CFTR) missense variant. The aim of our study was to describe the clinical features of a cohort of individuals carrying this variant. In parallel, by exploiting ex vivo functional and molecular analyses on nasal epithelia derived from a subset of S737F carriers, we evaluated its functional impact on CFTR protein as well as its responsiveness to CFTR modulators. We retrospectively collected clinical data of all individuals bearing at least one S737F CFTR variant and followed at the CF Centre of Tuscany region (Italy). Nasal brushing was performed in cooperating individuals. At study end clinical data were available for 10 subjects (mean age: 14 years; range 1–44 years; 3 adult individuals). Five asymptomatic subjects had CF, 2 were CRMS/CFSPID and 3 had an inconclusive diagnosis. Ex vivo analysis on nasal epithelia demonstrated different levels of CF activity. In particular, epithelia derived from asymptomatic CF subjects and from one of the subjects with inconclusive diagnosis showed reduced CFTR activity that could be rescued by treatment with CFTR modulators. On the contrary, in the epithelia derived from the other two individuals with an inconclusive diagnosis, the CFTR-mediated current was similar to that observed in epithelia derived from healthy donors. In vitro functional and biochemical analysis on S737F-CFTR expressed in immortalized bronchial cells highlighted a modest impairment of the channel activity, that was improved by treatment with ivacaftor alone or in combination with tezacaftor/elexacaftor. Our study provide evidence towards the evaluation of CFTR function on ex vivo nasal epithelial cell models as a new assay to help clinicians to classify individuals, in presence of discordance between clinical picture, sweat test and genetic profile.Keywords
Funding Information
- Cystic Fibrosis Foundation (PEDEMO20G0, FFC #10/2021)
- Italian Cystic Fibrosis Foundation (PEDEMO20G0, FFC #10/2021)
- Italian Ministry of Health (PEDEMO20G0, FFC #10/2021)
This publication has 32 references indexed in Scilit:
- Inconclusive Diagnosis of Cystic Fibrosis After Newborn ScreeningPediatrics, 2015
- Cystic fibrosis genetics: from molecular understanding to clinical applicationNature Reviews Genetics, 2014
- Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equationsEuropean Respiratory Journal, 2012
- Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profilingAmerican Journal of Physiology-Cell Physiology, 2011
- Recommendations for the classification of diseases as CFTR-related disordersJournal of Cystic Fibrosis, 2011
- Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary ExacerbationsAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders – updated European recommendationsEuropean Journal of Human Genetics, 2008
- Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practiceJournal of Cystic Fibrosis, 2008
- Diagnostic Sweat Testing: The Cystic Fibrosis Foundation GuidelinesThe Journal of Pediatrics, 2007
- Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patientsJournal of Cystic Fibrosis, 2003